Status:
UNKNOWN
Platelet-rich Plasma(PRP) Injection in ED
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Erectile Dysfunction
PRP
Eligibility:
MALE
20-70 years
Phase:
NA
Brief Summary
RPR contains rich-in growth factors and has the properties of helping tissue regeneration and nerve repair. In theory, it is possibility of curing ED.
Detailed Description
There are many reasons of erectile dysfunction(ED). If left untreated, there is a major impact on relationships, self-esteem, and overall health. RPR contains rich-in growth factors and has the proper...
Eligibility Criteria
Inclusion
- Male
- Between 20 and 70 years old
- Sexual dysfunction exists for at least 6 months
- IIEF-5 score 8-2
- Sign an informed consent form
Exclusion
- Ever radical prostatectomy or extensive pelvic surgery
- Radiation therapy to the pelvic area within 12 months before recruiting
- Cancer
- Nervous system diseases that affect erectile function
- Have any blood disease
- History of coronary artery disease
Key Trial Info
Start Date :
March 22 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 29 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05241964
Start Date
March 22 2021
End Date
November 29 2022
Last Update
February 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan